Cargando…
Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization
Plague caused by the Gram‐negative bacterium, Yersinia pestis, is still endemic in parts of the world today. Protection against pneumonic plague is essential to prevent the development and spread of epidemics. Despite this, there are currently no licensed plague vaccines in the western world. Here w...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514708/ https://www.ncbi.nlm.nih.gov/pubmed/30985006 http://dx.doi.org/10.1111/cei.13301 |
_version_ | 1783417923665133568 |
---|---|
author | Carvalho, A. L. Miquel‐Clopés, A. Wegmann, U. Jones, E. Stentz, R. Telatin, A. Walker, N. J. Butcher, W. A. Brown, P. J. Holmes, S. Dennis, M. J. Williamson, E. D. Funnell, S. G. P. Stock, M. Carding, S. R. |
author_facet | Carvalho, A. L. Miquel‐Clopés, A. Wegmann, U. Jones, E. Stentz, R. Telatin, A. Walker, N. J. Butcher, W. A. Brown, P. J. Holmes, S. Dennis, M. J. Williamson, E. D. Funnell, S. G. P. Stock, M. Carding, S. R. |
author_sort | Carvalho, A. L. |
collection | PubMed |
description | Plague caused by the Gram‐negative bacterium, Yersinia pestis, is still endemic in parts of the world today. Protection against pneumonic plague is essential to prevent the development and spread of epidemics. Despite this, there are currently no licensed plague vaccines in the western world. Here we describe the means of delivering biologically active plague vaccine antigens directly to mucosal sites of plague infection using highly stable microvesicles (outer membrane vesicles; OMVs) that are naturally produced by the abundant and harmless human commensal gut bacterium Bacteroides thetaiotaomicron (Bt). Bt was engineered to express major plague protective antigens in its OMVs, specifically Fraction 1 (F1) in the outer membrane and LcrV (V antigen) in the lumen, for targeted delivery to the gastrointestinal (GI) and respiratory tracts in a non‐human primate (NHP) host. Our key findings were that Bt OMVs stably expresses F1 and V plague antigens, particularly the V antigen, in the correct, immunogenic form. When delivered intranasally V‐OMVs elicited substantive and specific immune and antibody responses, both in the serum [immunoglobulin (Ig)G] and in the upper and lower respiratory tract (IgA); this included the generation of serum antibodies able to kill plague bacteria. Our results also showed that Bt OMV‐based vaccines had many desirable characteristics, including: biosafety and an absence of any adverse effects, pathology or gross alteration of resident microbial communities (microbiotas); high stability and thermo‐tolerance; needle‐free delivery; intrinsic adjuvanticity; the ability to stimulate both humoral and cell‐mediated immune responses; and targeting of primary sites of plague infection. |
format | Online Article Text |
id | pubmed-6514708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65147082019-05-21 Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization Carvalho, A. L. Miquel‐Clopés, A. Wegmann, U. Jones, E. Stentz, R. Telatin, A. Walker, N. J. Butcher, W. A. Brown, P. J. Holmes, S. Dennis, M. J. Williamson, E. D. Funnell, S. G. P. Stock, M. Carding, S. R. Clin Exp Immunol Editor's Choice Plague caused by the Gram‐negative bacterium, Yersinia pestis, is still endemic in parts of the world today. Protection against pneumonic plague is essential to prevent the development and spread of epidemics. Despite this, there are currently no licensed plague vaccines in the western world. Here we describe the means of delivering biologically active plague vaccine antigens directly to mucosal sites of plague infection using highly stable microvesicles (outer membrane vesicles; OMVs) that are naturally produced by the abundant and harmless human commensal gut bacterium Bacteroides thetaiotaomicron (Bt). Bt was engineered to express major plague protective antigens in its OMVs, specifically Fraction 1 (F1) in the outer membrane and LcrV (V antigen) in the lumen, for targeted delivery to the gastrointestinal (GI) and respiratory tracts in a non‐human primate (NHP) host. Our key findings were that Bt OMVs stably expresses F1 and V plague antigens, particularly the V antigen, in the correct, immunogenic form. When delivered intranasally V‐OMVs elicited substantive and specific immune and antibody responses, both in the serum [immunoglobulin (Ig)G] and in the upper and lower respiratory tract (IgA); this included the generation of serum antibodies able to kill plague bacteria. Our results also showed that Bt OMV‐based vaccines had many desirable characteristics, including: biosafety and an absence of any adverse effects, pathology or gross alteration of resident microbial communities (microbiotas); high stability and thermo‐tolerance; needle‐free delivery; intrinsic adjuvanticity; the ability to stimulate both humoral and cell‐mediated immune responses; and targeting of primary sites of plague infection. John Wiley and Sons Inc. 2019-04-15 2019-06 /pmc/articles/PMC6514708/ /pubmed/30985006 http://dx.doi.org/10.1111/cei.13301 Text en © 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Editor's Choice Carvalho, A. L. Miquel‐Clopés, A. Wegmann, U. Jones, E. Stentz, R. Telatin, A. Walker, N. J. Butcher, W. A. Brown, P. J. Holmes, S. Dennis, M. J. Williamson, E. D. Funnell, S. G. P. Stock, M. Carding, S. R. Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization |
title | Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization |
title_full | Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization |
title_fullStr | Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization |
title_full_unstemmed | Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization |
title_short | Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization |
title_sort | use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization |
topic | Editor's Choice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514708/ https://www.ncbi.nlm.nih.gov/pubmed/30985006 http://dx.doi.org/10.1111/cei.13301 |
work_keys_str_mv | AT carvalhoal useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT miquelclopesa useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT wegmannu useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT jonese useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT stentzr useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT telatina useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT walkernj useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT butcherwa useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT brownpj useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT holmess useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT dennismj useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT williamsoned useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT funnellsgp useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT stockm useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization AT cardingsr useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization |